text:
NIK–IKK complex interaction controls NF-κB-dependent inflammatory activation of endothelium in response to LTβR ligation
Paulina Kucharzewska, Chrissta X. Maracle, Kim C. M. Jeucken, Jan Piet van Hamburg, Elisabeth Israelsson, Mark Furber, Sander W. Tas, Henric K. Olsson
Journal of Cell Science 2019 132: jcs225615 doi: 10.1242/jcs.225615 Published 3 April 2019
Paulina Kucharzewska
1Respiratory, Inflammation and Autoimmunity IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden
ORCID record for Paulina Kucharzewska
For correspondence: paulina_kucharzewska_siembieda@sggw.pl
Chrissta X. Maracle
2Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology and Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center/University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Kim C. M. Jeucken
Jan Piet van Hamburg
Elisabeth Israelsson
Mark Furber
Sander W. Tas
Henric K. Olsson
Supp info
PDF + SI
NF-κB-inducing kinase (NIK; also known as MAP3K14) is a central regulator of non-canonical NF-κB signaling in response to stimulation of TNF receptor superfamily members, such as the lymphotoxin-β receptor (LTβR), and is implicated in pathological angiogenesis associated with chronic inflammation and cancer. Here, we identify a previously unrecognized role of the LTβR–NIK axis during inflammatory activation of human endothelial cells (ECs). Engagement of LTβR-triggered canonical and non-canonical NF-κB signaling promoted expression of inflammatory mediators and adhesion molecules, and increased immune cell adhesion to ECs. Sustained LTβR-induced inflammatory activation of ECs was NIK dependent, but independent of p100, indicating that the non-canonical arm of NF-κB is not involved. Instead, prolonged activation of canonical NF-κB signaling, through the interaction of NIK with IκB kinase α and β (also known as CHUK and IKBKB, respectively), was required for the inflammatory response. Endothelial inflammatory activation induced by synovial fluid from rheumatoid arthritis patients was significantly reduced by NIK knockdown, suggesting that NIK-mediated alternative activation of canonical NF-κB signaling is a key driver of pathological inflammatory activation of ECs. Targeting NIK could thus provide a novel approach for treating chronic inflammatory diseases.
Vascular endothelial cells (ECs) are crucial participants and regulators of normal immune and inflammatory responses (Pober and Sessa, 2007), and endothelial dysfunction may play a central role in the pathogenesis of chronic inflammatory diseases, e.g. rheumatoid arthritis (RA) (Murdaca et al., 2012; Noort et al., 2015a; Steyers and Miller, 2014; Al-Soudi et al., 2017). As a driver of chronic inflammation in RA, endothelial dysfunction involves pathological responses of ECs, such as inflammatory activation, angiogenesis, high endothelial venule (HEV) differentiation and tertiary lymphoid organ (TLO) formation. Upon inflammatory activation, ECs express adhesion molecules and produce chemokines, thereby recruiting immune cells into the synovial tissue (Murdaca et al., 2012; Steyers and Miller, 2014; Al-Soudi et al., 2017). Angiogenesis is driven by activated stromal and inflammatory cells secreting angiogenic factors, e.g. VEGFA, that trigger quiescent ECs to differentiate and form new blood vessels, which contribute to persistent inflammation (Elshabrawy et al., 2015). TLOs are formed in a process of lymphoid neogenesis, involving conversion of chronic inflammatory infiltrates into organized lymphoid tissue with HEV and sometimes even true germinal centers. These aggregates seem to facilitate the process of epitope spreading associated with autoimmunity and may exacerbate inflammation (Humby et al., 2009; Pitzalis et al., 2014; Noort et al., 2015a; Jones and Jones, 2016). Given the central role of endothelial dysfunction in the pathophysiology of inflammatory diseases, signaling pathways that control EC activation have been extensively studied, and the NF-κB family of transcription factors has been identified as critical for expression of many of the genes associated with EC pathology (Pober and Sessa, 2007; Tas et al., 2016).
The nuclear factor-κB (NF-κB) transcription factors operate as heterodimers with a predominance for pairing of p50 (also known as NFKB1)/p65 (also known as RELA), p50/c-Rel and p52 (also known as NFKB2)/RelB (Hayden and Ghosh, 2004; Napetschnig and Wu, 2013). Activation of canonical NF-κB signaling in response to pro-inflammatory stimuli, such as TLR ligands, IL-1β and TNFα (also known as TNF) leads to ubiquitin-dependent degradation of IκBα (also known as NFKBIA), and, as a consequence, nuclear translocation of NF-κB complexes, especially p50/p65 heterodimers. Degradation of IκBα is triggered by its phosphorylation by the trimeric IκB kinase (IKK) complex, which is composed of two catalytic subunits, IKKα (also known as CHUK) and IKKβ (also known as IKBKB), and a regulatory subunit, IKKγ [also known as NF-κB essential modulator (NEMO) or IKBKG] (Hayden and Ghosh, 2004; Napetschnig and Wu, 2013). In contrast, the non-canonical NF-κB pathway is strictly dependent on NF-κB-inducing kinase (NIK; also known as MAP3K14), which activates IKKα to phosphorylate the p100/NF-κB2 precursor protein, leading to its processing to p52 (Napetschnig and Wu, 2013; Sun, 2017), followed by nuclear translocation of p52:RelB heterodimers and, ultimately, target gene transcription (Bonizzi et al., 2004; Lovas et al., 2008; Madge et al., 2008; Kew et al., 2012). This pathway is activated via TNF receptor superfamily members, such as the lymphotoxin-β receptor (LTβR), B-cell-activating factor receptor (BAFFR; also known as TNFRSF13C) and CD40. All known inducers of the non-canonical NF-κB pathway can also activate canonical NF-κB signaling, but to what extent may vary between stimuli (Napetschnig and Wu, 2013; Sun, 2017).
Whereas the role of canonical NF-κB signaling in inflammatory activation of ECs and angiogenesis is well established (De Martin et al., 2000; Huang et al., 2000; Kempe et al., 2005; Pober and Sessa, 2007; Tas et al., 2016), the function of non-canonical NF-κB signaling in ECs, especially in the context of inflammation, is less defined. Previous studies have shown that ECs express LTβR and CD40, and that the ligation of LTβR results in expression of CXCL12 in a non-canonical NF-κB-dependent manner (Hollenbaugh et al., 1995; Chang et al., 2005; Madge et al., 2008). Recently, it was demonstrated that LTβR signaling in ECs is crucial for the development and function of HEVs and lymph node homing of lymphocytes (Onder et al., 2013). Interestingly, NIK-positive HEVs are also present at sites of chronic inflammation, such as RA synovial tissue, indicating that NIK and the non-canonical NF-κB pathway may regulate TLO formation downstream of LTβR in chronic inflammation by regulating the development of the cuboidal HEV-like appearance and functions, including the acquisition of leukocyte traffic-regulating properties (Noort et al., 2015a). Additionally, NIK is activated in blood vessels of tumor tissues and inflamed RA synovial tissue, and promotes pathological angiogenesis in response to LTβR or CD40 ligation (Noort et al., 2014; Maracle et al., 2017). Furthermore, NIK expression in the blood vessels in the synovium of early RA patients is positively correlated with inflammatory cell infiltration and disease activity, as measured by joint swelling, erythrocyte sedimentation rate and C-reactive protein levels (Maijer et al., 2015), suggesting that, in addition to regulating pathological angiogenesis, NIK may also modulate the inflammatory phenotype of endothelium. However, the role of NIK and downstream NF-κB signaling during the inflammatory activation of ECs remains elusive. Improved molecular understanding of this pathway is needed to provide more insight into the pathogenesis of chronic inflammation, and, in this study, we identify NIK as a key mediator of inflammatory activation of ECs in response to LTβR ligation.
LTβR ligation activates canonical and non-canonical NF-κB signaling pathways and induces inflammation in ECs
To confirm LTβR-induced NF-κB signaling in ECs (Dejardin et al., 2002; Müller and Siebenlist, 2003; Madge et al., 2008; Wolf et al., 2010; Lau et al., 2014), we probed for non-canonical and canonical NF-κB activation in human umbilical vein ECs (HUVECs) stimulated with lymphotoxin α1/β2 (LTβ) or LIGHT (also known as TNFSF14). Both LTβ and LIGHT induced strong and dose-dependent activation of non-canonical NF-κB signaling in HUVECs, as shown by increased levels of NIK and p52 protein, the processed (activated) form of p100 protein (Fig. 1A; Fig. S1A). Activation of non-canonical NF-κB signaling in response to LTβR ligation was slow (i.e. only apparent after several hours) but long lasting (at least 48 h) (Fig. 1A). LTβ and LIGHT also induced classical NF-κB signaling in HUVECs (Fig. 1B); however, in contrast to non-canonical NF-κB signaling, the canonical pathway was activated within minutes by both cytokines, inducing IκBα degradation, with levels reaching a minimum at 30 min of stimulation and returning to baseline within 1 h of stimulation. LTβR ligation induced activation of the two NF-κB signaling pathways in a similar manner in the human vascular EC line EA.hy926 (Fig. S1B–D) and in human microvascular ECs (HMVECs) (Fig. S1F,G).
LTβR ligation induces canonical and non-canonical NF-κB signaling and drives inflammatory activation of ECs. (A) Immunoblot analysis of NIK, p100/p52 and tubulin as a loading control in HUVECs treated with LTβ (0.1 µg/ml) or LIGHT (0.1 µg/ml) for the indicated time points. Left panels: immunoblotting data from representative experiments. h, hours. Right panels: densitometric analysis of NIK and p52 bands from three independent experiments. (B) Immunoblot analysis of phospho-IκBα (p-IκBα; Ser32/36), IκBα and tubulin as a loading control in HUVECs treated with LTβ (0.1 µg/ml) or LIGHT (0.1 µg/ml) for the indicated time points. Left panels: immunoblotting data from representative experiments. min, minutes. Right panels: densitometric analysis of p-IκBα and IκBα bands from three independent experiments. (C) Quantification of NF-κB DNA binding activity by ELISA in nuclear protein extracts from HUVECs treated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for the indicated time points. (D) Real-time qPCR quantification of the CXCL1, CXCL5, CXCL8, GM-CSF, CCL2, CCL5, CCL20, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs treated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (E) Quantification of CXCL1, CXCL5, CXCL8 and CCL2 protein levels by MSD immunoassay platform in conditioned medium from HUVECs treated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 24 h. (F) Immunoblot analysis of VCAM-1 and tubulin as a loading control in HUVECs treated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for the indicated time points. Upper panel: immunoblotting data from a representative experiment. h, hours. Lower panel: densitometric analysis of VCAM-1 bands from three independent experiments. (G) Quantification of permeability of HUVEC monolayers treated with the indicated concentrations of LTβ or TNFα (0.01 µg/ml) for 24 h. (H) Adhesion of Jurkat cells (upper row), THP-1 cells (middle row) or human blood-derived neutrophils (lower row) to HUVECs treated with the indicated concentrations of LTβ for 24 h. Left panels: quantification of immune cell adhesion to HUVECs relative to control cells. Right panels: representative images of calcein-labeled leukocytes attached to HUVECs. Scale bars: 100 µm. Data represent mean±s.e.m. of three (A–D,F–H) or four (E) independent experiments. ns, not significant; *P≤0.05, **P≤0.01 versus control (one-way ANOVA and Tukey's HSD post hoc test).
LTβR-induced nuclear accumulation of NF-κB proteins in HUVECs followed similar pathway activation kinetics, with maximal nuclear localization of classical NF-κB proteins (p50 and p65) observed at 2 h of stimulation with LTβ and LIGHT, whereas nuclear accumulation of the non-canonical NF-κB proteins (RelB and p52) was much slower, requiring >8 h to reach maximal levels (Fig. 1C; Fig. S2A). We did not observe any substantial effect of LTβR ligation on nuclear localization of c-Rel (Fig. 1C).
NF-κB signaling is a key regulator of inflammatory responses, and, to assess the potential impact of LTβR-induced NF-κB activity on inflammatory activation of endothelium, we stimulated ECs with either LTβ or LIGHT and analyzed expression of NF-κB target genes. Both stimuli induced the expression of inflammatory cytokines and chemokines [CXCL1, CXCL5, CXCL8, GM-CSF (also known as CSF2), CCL2, CCL5, CCL20], as well as adhesion molecules mediating immune cell recruitment (ICAM-1, VCAM-1 and E-selectin), both at mRNA (Fig. 1D) and protein levels (Fig. 1E,F; Fig. S1I). Furthermore, LTβR ligation induced an increase in endothelial barrier permeability (Fig. 1G) and adhesion of Jurkat T cells (Fig. 1H, upper row; Fig. S1E,H, left panels), THP-1 monocytes (Fig. 1H, middle row; Fig. S1E,H, right panels) and blood-derived neutrophils (Fig. 1H, lower row) to activated endothelium. Together, these results demonstrate that LTβR ligation activates both the canonical and non-canonical NF-κB signaling pathways and drives inflammatory activation of ECs.
Inflammatory activation of ECs in response to LTβR ligation is NIK dependent
To determine whether LTβR-induced canonical NF-κB signaling and inflammatory activation of ECs is NIK dependent, we transfected ECs with either scrambled small interfering RNA (siRNA; siScr) or siRNA targeting NIK (siNIK) (Fig. S3), and stimulated them with LTβ or LIGHT for short (up to 30 min) or long (3 h) time points. Knockdown of NIK in ECs had no effect on the acute activation of canonical NF-κB upon LTβR ligation (Fig. S4A,B), whereas after 3 h of stimulation with LTβ or LIGHT, both HUVECs (Fig. 2A; Fig. S5A) and EA.hy926 cells (Fig. S5E) transfected with siRNA targeting NIK exhibited significantly impaired activation of canonical NF-κB signaling. Accordingly, NIK knockdown in HUVECs (Fig. 2B; Fig. S2B) and EA.hy926 cells (Figs S2C, S5F) resulted in decreased p50 nuclear translocation in response to long-term stimulation with LTβ or LIGHT compared with cells transfected with siScr.
NIK is required for the induction of canonical NF-κB pathway and inflammatory activation of ECs upon LTβR ligation. (A) Immunoblot analysis of NIK, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transfected with scrambled siRNA (siScr; 10 nM) or siRNA targeting NIK (siNIK; 10 nM) and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 3 h. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent NIK and p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Middle and right panels: densitometric analysis of NIK and p-IκBα bands from seven independent experiments. (B) Quantification of p50 DNA-binding activity by ELISA in nuclear protein extracts from HUVECs transfected with siScr or siNIK as in A, and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (C) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transfected with siScr or siNIK as in A, and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (D) Quantification of CXCL1, CXCL5, CXCL8 and CCL2 protein levels by MSD immunoassay platform in conditioned medium from HUVECs transfected with siScr or siNIK as in A, and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 24 h. (E) Immunoblot analysis of VCAM-1 and tubulin as a loading control in HUVECs transfected with siScr or siNIK as in A, and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 24 h. Upper panel: immunoblotting data from a representative experiment. Lower panel: densitometric analysis of VCAM-1 bands from three independent experiments. (F,G) Adhesion of Jurkat cells (F) or THP-1 cells (G) to HUVECs transfected with siScr or siNIK as in A and incubated with LTβ (0.25 µg/ml) for 24 h. Left panels: representative images of calcein-labeled leukocytes attached to HUVECs. Scale bars: 100 µm. Right panels: quantification of immune cell adhesion to HUVECs relative to siScr. (H) Immunoblot analysis of p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs treated with DMSO or NIK inhibitor (NIKi; 2.5 µM) for 30 min, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 3 h. Cells were treated with proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Right panel: densitometric analysis of p-IκBα bands from two independent experiments. (I) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs treated with DMSO or NIKi as in H, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (J) Adhesion of Jurkat cells to HUVECs treated with DMSO or the indicated concentrations of NIKi for 30 min, followed by stimulation with LTβ (0.25 µg/ml) for 24 h. Data represent mean±s.e.m. of two (H), three (B,C,E–G,I,J), four (D) or seven (A) independent experiments. ns, not significant; *P≤0.05, **P≤0.01 [one-way ANOVA and Tukey's HSD post hoc test (A–E,H–J) or Student's t-test (F,G)].
Having demonstrated that NIK regulates canonical NF-κB signaling downstream of the LTβR, we next explored whether NIK activity is required also for the inflammatory activation of ECs in response to LTβR ligation. Knockdown of NIK impaired inflammatory activation (expression of inflammatory cytokines and adhesion molecules) of ECs in response to LTβR ligation (Fig. 2C–E; Fig. S5B,C,H), and led to diminished adhesion of Jurkat T cells (Fig. 2F; Fig. S5D, left panel) and THP-1 monocytes (Fig. 2G; Fig. S5D, right panel) to EC monolayers. Similar effects were obtained in ECs treated with the pharmacological NIK inhibitor to block NIK kinase activity (Fig. 2H–J; Figs S4C,D, S5G and S6A,B), indicating that the capacity of LTβR to sustain long-term phosphorylation of IκBα in ECs requires accumulation and kinase activity of NIK.
As complement to the loss-of-function experiments, we next overexpressed NIK in ECs. HUVECs were infected with adenoviral vectors expressing wild-type NIK (AdNIK-WT), kinase-dead NIK (AdNIK-KD) or GFP (AdGFP) as a control. NIK overexpression in HUVECs induced ligand-independent activation of the canonical NF-κB pathway in a concentration-dependent manner [increased levels of phospho-IκBα (p-IκBα) and p50/p65 nuclear translocation], whereas transduction with AdGFP or AdNIK-KD vectors did not (Fig. 3A,B; Fig. S2D), confirming the conclusion based on pharmacological inhibition of NIK that NIK kinase activity is required for the activation of the canonical NF-κB pathway in ECs. In line with these results, overexpression of wild-type NIK in HUVECs resulted in increased expression of inflammatory cytokines and adhesion molecules compared with cells transduced with AdGFP or AdNIK-KD (Fig. 3C,D). Together, these data show that accumulation of kinase active NIK is required for full activation of the canonical NF-κB pathway and inflammatory activation of ECs in response to LTβR ligation.
Ligand-independent activation of canonical NF-κB pathway in ECs overexpressing NIK. (A) Immunoblot analysis of NIK, p100/p52, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transduced with adenoviral vectors expressing GFP (AdGFP), wild-type NIK (AdNIK-WT) or kinase-dead NIK (AdNIK-KD) at 10, 100, 250 and 500 multiplicities of infection (MOIs). Cells were treated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Right three panels: densitometric analysis of NIK, p52 and p-IκBα bands from three independent experiments. (B) Quantification of p50 and p65 DNA-binding activity by ELISA in nuclear protein extracts from HUVECs transduced with AdGFP, AdNIK-WT or AdNIK-KD (250 MOIs). (C) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transduced with AdGFP, AdNIK-WT or AdNIK-KD as in A. (D) Quantification of CXCL1, CXCL5, CXCL8 and GM-CSF protein levels by MSD immunoassay platform in conditioned medium from HUVECs transduced with AdGFP, AdNIK-WT or AdNIK-KD (100 and 500 MOIs). Data represent mean±s.e.m. of three independent experiments. ns, not significant; *P≤0.05, **P≤0.01 versus AdGFP (one-way ANOVA and Tukey's HSD post hoc test).
Dispensable role of p100 in NIK-dependent activation of canonical NF-κB signaling in response to LTβR ligation
NIK activates the non-canonical NF-κB pathway by inducing phosphorylation of IKKα and p100, leading to p100 processing to p52 protein and its nuclear translocation (Ling et al., 1998; Xiao et al., 2001). To explore whether NIK-dependent regulation of canonical NF-κB signaling in ECs is mediated by p100, we knocked down p100 expression using an siRNA approach before stimulation with LTβ or LIGHT. Silencing p100 expression in HUVECs and EA.hy926 cells had no effect on LTβR-induced activation of canonical NF-κB signaling (Fig. 4A,B) and did not affect the inflammatory activation of ECs in response to LTβR ligation, as shown by unaffected gene expression of inflammatory molecules (Fig. 4C) and immune cell adhesion to activated endothelium (Fig. 4D). To specifically show that NIK-mediated regulation of canonical NF-κB activity in response to LTβR ligation is p100 independent, p100 expression in HUVECs was knocked down using siRNA before overexpression of wild-type NIK (AdNIK-WT) or the control vector (AdGFP). Enhanced activation of the canonical NF-κB pathway induced by NIK overexpression in ECs was not impaired by p100 knockdown (Fig. 4E), suggesting that NIK-mediated activation of the canonical NF-κB pathway downstream of the LTβR is direct and independent of activation of non-canonical NF-κB signaling.
Dispensable role of p100 in NIK-driven activation of canonical NF-κB pathway in ECs upon LTβR ligation. (A,B) Immunoblot analysis of p100, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs (A) and EA.hy926 cells (B) transfected with scrambled siRNA (siScr; 10 nM) or siRNAs targeting p100 (sip100-1 or sip100-2; 10 nM) and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 3 h. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Upper panels: immunoblotting data from representative experiments. Lower panels: densitometric analysis of p-IκBα bands from three independent experiments. (C) Real-time qPCR quantification of the CXCL8, CCL5 and VCAM-1 transcripts expressed in HUVECs transfected with siScr or sip100 as in A and stimulated with LTβ (0.25 µg/ml) for 6 h. (D) Adhesion of Jurkat cells (left panel) and THP-1 cells (right panel) to HUVECs transfected with siScr or sip100 as in A, and stimulated with LTβ (0.25 µg/ml) for 24 h. (E) Immunoblot analysis of NIK, p100, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transfected with siScr or sip100 as in A, and transduced with adenoviral vectors expressing GFP (AdGFP) or wild-type NIK (AdNIK-WT) at 250 MOIs. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Right panel: densitometric analysis of p-IκBα bands from three independent experiments. Data represent mean±s.e.m. of two (C), three (A,B,E) or four (D) independent experiments. ns, not significant; **P≤0.01 (one-way ANOVA and Tukey's HSD post hoc test).
NIK drives inflammatory activation of ECs upon LTβR ligation through the IKK complex
To explore whether NIK and the IKK complex interact to regulate LTβR-induced inflammatory activation of ECs by driving sustained phosphorylation of IκBα, we silenced IKKα in ECs before stimulation with LTβ or LIGHT. In both HUVECs (Fig. 5A) and EA.hy926 cells (Fig. S7A), IKKα knockdown resulted in significantly decreased activation of canonical NF-κB signaling in response to stimulation with LTβ or LIGHT. Also, IKKα knockdown resulted in impaired inflammatory activation in response to LTβR ligation, as shown by significantly decreased gene expression of inflammatory cytokines and adhesion molecules compared with siScr cells (Fig. 5B). Furthermore, siRNA-mediated knockdown of IKKα in HUVECs that overexpressed NIK (AdNIK-WT) effectively blocked activation of the canonical NF-κB pathway (Fig. 5C) and inflammatory activation (gene expression of inflammatory cytokines and adhesion molecules) (Fig. 5D). Therefore, IKKα activity appears essential for NIK-dependent activation of canonical NF-κB signaling pathway downstream of LTβR ligation.
NIK-driven canonical NF-κB signaling in response to LTβR ligation depends on intact IKKα activity. (A) Immunoblot analysis of IKKα, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transfected with scrambled siRNA (siScr; 10 nM) or siRNAs targeting IKKα (siIKKα-1 or siIKKα-2; 10 nM) and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 3 h. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Right panel: densitometric analysis of p-IκBα bands from five independent experiments. (B) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transfected with siScr or siIKKα as in A, and stimulated with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (C) Immunoblot analysis of NIK, IKKα, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transfected with siScr or siIKKα as in A, and transduced with adenoviral vectors expressing GFP (AdGFP) or wild-type NIK (AdNIK-WT) at 250 MOIs. Left panel: immunoblotting data from a representative experiment. Right panel: densitometric analysis of p-IκBα bands from four independent experiments. (D) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transfected with siScr or siIKKα as in A, and transduced with AdGFP or AdNIK-WT (250 MOIs). Data represent mean±s.e.m. of two (B), four (C,D) or five (A) independent experiments. *P≤0.05, **P≤0.01 (one-way ANOVA and Tukey's HSD post hoc test).
IKKα and IKKβ both phosphorylate the IκB proteins, leading to the subsequent activation of NF-κB. However, IKKβ exhibits stronger kinase activity for the IκB proteins and evokes a more robust activation of the canonical NF-κB pathway than IKKα (Woronicz et al., 1997; Li et al., 1998, 1999; Hu et al., 1999; Tanaka et al., 1999; Adli et al., 2010), implicating IKKβ in the induction of the canonical NF-κB pathway downstream of the NIK–IKKα axis in ECs in response to LTβR ligation. In support of this hypothesis, activation of IKKα in response to either TNFα or overexpression of NIK has been shown to result in phosphorylation and activation of IKKβ (O'Mahony et al., 2000; Yamamoto et al., 2000). To determine the role of IKKβ in mediating the pro-inflammatory activity of the NIK–IKKα axis in ECs upon LTβR ligation, the effect of pharmacological inhibition of IKKβ kinase activity or siRNA-mediated knockdown of IKKβ on LTβR-induced IκBα phosphorylation was studied. Both HUVECs and EA.hy926 cells treated with an IKKβ inhibitor (IKKβi) exhibited complete inhibition of canonical NF-κB signaling (Fig. 6A; Figs S6C,D and S7B), and, in HUVECs, a strong reduction in inflammatory activation (decreased expression of inflammatory cytokines and adhesion molecules as well as diminished adhesion of immune cells) in response to LTβR ligation was observed (Fig. 6B–E). Similarly, siRNA-mediated knockdown of IKKβ in HUVECs resulted in inhibition of canonical NF-κB signaling (Fig. S7C,D), and a strong reduction in inflammatory activation (decreased expression of inflammatory cytokines and adhesion molecules) in response to LTβR ligation (Fig. S7E).
NIK–IKKα complex requires IKKβ for the activation of canonical NF-κB signaling in ECs upon LTβR ligation. (A) Immunoblot analysis of p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs treated with DMSO or IKKβ inhibitor (IKKβi; 2.5 µM) for 30 min, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 3 h. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Upper panel: immunoblotting data from a representative experiment. Lower panel: densitometric analysis of p-IκBα bands from four independent experiments. (B) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs treated with DMSO or IKKβi as in A, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 6 h. (C) Quantification of CXCL1, CXCL5, CXCL8 and CCL-2 protein levels by MSD immunoassay platform in conditioned medium from HUVECs treated with DMSO or IKKβi as in A, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 24 h. (D) Immunoblot analysis of VCAM-1 and tubulin as a loading control in HUVECs treated with DMSO or IKKβi as in A, followed by stimulation with LTβ (0.25 µg/ml) or LIGHT (0.25 µg/ml) for 24 h. Upper panel: immunoblotting data from a representative experiment. Lower panel: densitometric analysis of VCAM-1 bands from three independent experiments. (E) Adhesion of Jurkat cells (left panel) and THP-1 cells (right panel) to HUVECs treated with DMSO or IKKβi at the indicated concentrations for 30 min, followed by stimulation with LTβ (0.25 µg/ml) for 24 h. (F) Immunoblot analysis of NIK, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transduced with adenoviral vectors expressing GFP (AdGFP) or wild-type NIK (AdNIK-WT) at 250 MOIs, followed by treatment with DMSO or IKKβi (2.5 µM) for 16 h. Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative experiment. Right panel: densitometric analysis of p-IκBα bands from four independent experiments. (G) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL5, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transduced with AdGFP or AdNIK-WT (250 MOIs), followed by treatment with DMSO or IKKβi (2.5 µM) for 16 h. Data represent mean±s.e.m. of three (B,D,E,G) or four (A,C,F) independent experiments. ns, not significant; *P≤0.05, **P≤0.01 [one-way ANOVA and Tukey's HSD post hoc test (A–E) or Student's t-test (F,G)].
To unambiguously show that IKKβ acts downstream of the NIK–IKKα axis in activating canonical NF-κB signaling, HUVECs overexpressing NIK (AdNIK-WT) were treated with the IKKβi or dimethyl sulfoxide (DMSO) as a control, followed by analysis of p-IκBα and gene expression. IKKβ inhibition resulted in profound suppression of NIK-mediated activation of canonical NF-κB signaling, placing NIK upstream of IKKβ in activating the canonical NF-κB pathway in response to LTβR ligation (Fig. 6F). In line with these data, inhibition of IKKβ in HUVECs overexpressing NIK resulted in decreased inflammatory activation of these cells (Fig. 6G). Taken together, our data demonstrate that NIK regulates the canonical NF-κB signaling pathway downstream of LTβR ligation by amplifying IKK complex activity.
NIK is involved in inflammatory activation of ECs induced by RA synovial fluid
Synovial fluid obtained from RA patients contains high levels of pro-inflammatory stimuli, including LTβ, LIGHT, CD40 and BAFF (also known as TNFSF13B), which are all able to induce NIK and non-canonical NF-κB signaling downstream of their respective receptors (Noort et al., 2015b; Maracle et al., 2017). Moreover, NIK is highly expressed in blood vessels in RA synovial tissues (Noort et al., 2014; Noort et al., 2015a), suggesting a role for NIK in inflammatory activation of ECs in RA. To explore whether NIK-mediated inflammatory activation of the endothelium might be a relevant biological driver of disease, HUVECs were stimulated with four different pools of RA synovial fluid (RASF) and then analyzed for the induction of NF-κB signaling and inflammatory activation. RASF activated both the non-canonical and canonical NF-κB pathways in a concentration-dependent manner in HUVECs, as shown by increased levels of p52 and p-IκBα, respectively (Fig. 7A). In addition, RASF-treated HUVECs exhibited increased expression of inflammatory cytokines and adhesion molecules, indicating inflammatory activation of ECs in response to RASF treatment (Fig. 7B). Knockdown of NIK, as shown by impaired generation of p52, resulted in reduced activation of canonical NF-κB signaling induced by RASF treatment (Fig. 7C). This effect translated to diminished inflammatory activation of ECs, as shown by decreased gene expression of inflammatory cytokines and adhesion molecules after RASF treatment (Fig. 7D), suggesting that NIK is important for inflammatory activation of ECs in RA (Fig. 8).
NIK regulates RASF-mediated inflammatory activation of ECs. (A) Immunoblot analysis of p100/p52, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs stimulated with RASF at the indicated concentrations for 3 h (p-IκBα detection) or 6 h (p52 detection). Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Left panel: immunoblotting data from a representative RASF pool. Middle and right panels: densitometric analysis of p52 and p-IκBα bands from four independent RASF pools. (B) Real-time qPCR quantification of the CXCL1, CXCL5, GM-CSF, CCL2, CCL20, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs stimulated with RASF at the indicated concentrations for 6 h. (C) Immunoblot analysis of p100/p52, p-IκBα (Ser32/36) and tubulin as a loading control in HUVECs transfected with scrambled siRNA (siScr; 10 nM) or siRNA targeting NIK (siNIK; 10 nM) and stimulated with RASF at the indicated concentrations for 3 h (p-IκBα detection) or 6 h (p52 detection). Cells were incubated with the proteasome inhibitor MG132 (50 μM) for the final hour to prevent p-IκBα degradation. Upper panel: immunoblotting data from a representative RASF pool. Lower panel: densitometric analysis of p-IκBα bands from four independent RASF pools. (D) Real-time qPCR quantification of the CXCL5, GM-CSF, CCL2, ICAM-1, VCAM-1 and E-selectin transcripts expressed in HUVECs transfected with siScr or siNIK as in C, and stimulated with RASF at the indicated concentrations for 6 h. Data represent mean±s.e.m. of four independent RASF pools. ns, not significant; *P≤0.05, **P≤0.01 versus control (one-way ANOVA and Tukey's HSD post hoc test).
Schematic model of LTβR ligation-induced inflammatory signaling in vascular ECs. LTβR ligation is driven by two major ligands, LTβ and LIGHT, and results in activation of both canonical (1) and non-canonical (2) NF-κB signaling pathways, distinguishing it from pro-inflammatory cytokines, such as TNFα and IL-1β, that only induce the canonical mechanism (3). Long-term ligation of LTβR in ECs, leading to accumulation of NIK, drives angiogenesis and cytokine/chemokine secretion via the non-canonical NF-κB pathway (Noort et al., 2014), as well as vascular inflammation via activation of the IKK complex in an NIK- and IKKα-dependent manner (4). Consequently, in addition to regulating non-canonical signaling, NIK can serve as an amplifier of canonical NF-κB signaling and associated inflammatory responses in ECs, which may play a role in development and maintenance of chronic inflammation.
Here, we provide evidence that LTβR signaling drives inflammatory activation of endothelium through the canonical NF-κB pathway in a manner dependent on accumulation of NIK protein. Furthermore, we show that NIK activates the canonical NF-κB pathway by enhancing IKK complex activity, implicating NIK as a proximal signaling molecule that activates both the canonical and non-canonical NF-κB pathways downstream of LTβR. The observation that LTβR stimulation can drive inflammatory activation of ECs through NF-κB is in line with a previous report (Madge et al., 2008), except that, in this study, the authors did not identify NIK as a regulator of the canonical NF-κB pathway, as they focused on immediate events after receptor ligation rather than sustained signaling through NIK. Our study clearly shows that accumulation of kinase active NIK over time is required for full activation of the canonical NF-κB pathway and inflammation in ECs in response to LTβR ligation, distinguishing it from NF-κB signaling induced by e.g. TNFα and IL-1β.
As was previously demonstrated in other cell types (Matsushima et al., 2001; Smith et al., 2001; Yin et al., 2001; Ramakrishnan et al., 2004; Zarnegar et al., 2008), we found that NIK is required for phosphorylation of IκBα in ECs, indicating that NIK regulates NF-κB signaling through activation of the IKK complex downstream of the LTβR in ECs. We also show that p100 is dispensable for NIK-dependent activation of the IKK complex and phosphorylation of IκBα upon LTβR ligation. Interestingly, it has been previously reported that the canonical NF-κB pathway can be regulated independently of the IKK complex through the C-terminus of p100 (termed IκBδ; also known as NFKBID), which, acting as an IκB protein, can bind canonical Rel proteins and thereby prevent their nuclear translocation (Scheinman et al., 1993; Novack et al., 2003). This suggests that NIK-dependent activation of canonical NF-κB activity upon LTβR ligation could result from a combination of increased induction of the IKK complex and processing of the C-terminus of p100. However, we observed that inflammatory activation of ECs in response to LTβR ligation is p100 independent, indicating that p100-mediated activation of canonical NF-κB signaling may be cell-type or stimulus specific, which remains to be determined in future studies.
Moreover, we demonstrate that IKKα and IKKβ are required for NIK-dependent activation of the canonical NF-κB pathway downstream of the LTβR in ECs, although the reciprocal regulation of IKKα and IKKβ is not distinguished. However, based on previous reports showing that activation of IKKα by NIK leads to phosphorylation and activation of IKKβ, and subsequently to IKKβ-mediated phosphorylation of IκBα (Woronicz et al., 1997), it is likely that this mechanism also accounts for canonical NF-κB activation in ECs upon LTβR ligation or NIK overexpression. Whether stimulation of other TNFR superfamily members, like CD40, also results in NIK-mediated activation of canonical NF-κB signaling in ECs remains to be determined (Seigner et al., 2018).
We show that NIK and IKKα are required for sustained activation of the canonical NF-κB pathway through the IKK complex in response to LTβR ligation in ECs, but we cannot exclude that other mechanisms mediated by these kinases may regulate the canonical NF-κB pathway and inflammatory activation of endothelium downstream of LTβR ligation. For instance, IKKα has also been described to have nuclear functions and serve as a regulator of canonical NF-κB dependent gene expression through control of promoter-associated, cytokine-induced phosphorylation and subsequent acetylation of specific residues in histone H3 (Anest et al., 2003; Yamamoto et al., 2003). In this context, NIK may regulate phosphorylation of histone H3 by inducing phosphorylation and activation of IKKα (Park et al., 2006). Alternatively, LTβR ligation may induce NIK-mediated activation of STAT3 as observed in prostate cancer cells (Nadiminty et al., 2007). STAT3 has been shown to maintain constitutive NF-κB activity and act synergistically with NF-κB to regulate several pro-inflammatory genes (e.g. IL-6) (Lee et al., 2009; Yoon et al., 2012; Yu et al., 2014), and it is possible that STAT3 is involved in NIK-dependent inflammatory activation of ECs in response to LTβR.
In regards to the relevance for chronic inflammatory diseases, we demonstrate that treatment of ECs with RASF drives activation of both canonical and non-canonical NF-κB signaling and inflammatory activation of ECs. This is in agreement with previous reports showing that stimuli that are able to induce canonical and non-canonical NF-κB signaling are abundantly present in the inflamed joints of RA patients, i.e. in synovial tissue or fluid, along with expression of the corresponding receptors on the surface of ECs (Noort et al., 2015b; Maracle et al., 2017). Consequently, both canonical and non-canonical NF-κB pathways are activated in blood vessels of the inflamed RA synovium (Noort et al., 2014, 2015a; Maracle et al., 2017). Importantly, our data further show that inhibition of NIK activity in ECs impairs activation of the canonical NF-κB pathway and prevents the induction of a pro-inflammatory phenotype in response to RASF, implicating NIK as a key regulator of pathological, inflammatory activation of endothelium. The incomplete inhibition of RASF-induced inflammatory activation of ECs after targeting NIK is likely explained by the composition of RASF, which is known to contain a plethora of pro-inflammatory molecules, including TNFα and IL-1β, which are capable of inducing canonical NF-κB signaling and inflammatory responses in ECs independently of NIK (Matsushima et al., 2001; Yin et al., 2001; Ramakrishnan et al., 2004).
In preclinical models, it has been established that mice lacking NIK are resistant to arthritis induction in the adjuvant-induced arthritis model, and have reduced inflammation-induced angiogenesis, osteoclastogenesis and bone erosions (Aya et al., 2005; Noort et al., 2014). Our finding that NIK inhibition impairs inflammatory activation of ECs in response to RASF suggests that the decreased severity of arthritis and histological inflammation scores in Nik−/− mice may be, at least in part, due to impaired inflammatory activation of endothelium and as a consequence of reduced influx of immune cells into the synovial tissue.
In conclusion, we demonstrate that NIK is critically involved in inflammatory activation of ECs in response to LTβR ligation (Fig. 8), and further identify NIK as a potentially novel therapeutic target for alleviating the pathological endothelium phenotype induced by canonical and non-canonical NF-κB signaling at sites of chronic inflammation.
Recombinant human proteins LTβ and LIGHT were purchased from R&D Systems. Antibodies against NIK (#4994), p-IκBα (#9246), IκBα (#9242) and IKKα (#2682) were from Cell Signaling Technology. Antibodies against VCAM-1 (ab134047), lamin B1 (ab133741) and α-tubulin (ab4074) were from Abcam. Anti-p100/NF-κB2 antibody was purchased from EMD Millipore (#05-361). Antibody against β-actin (sc-47778) was purchased from Santa Cruz Biotechnology. MG132 and fluorescein isothiocyanate (FITC)-conjugated dextran (10 kDa) were purchased from Sigma-Aldrich. Calcein-AM was from Thermo Fisher Scientific. The pharmacological inhibitors of NIK and IKKβ were resynthesized by AstraZeneca (Gothenburg, Sweden), following the patented procedures (Andersson et al., 2008; Hynd et al., 2014). RASF was collected during mini-arthroscopy as described previously (Kraan et al., 2002), pooled from four patients and used at various concentrations. Patient consent was obtained for all participants in written format according to the Declaration of Helsinki.
Primary HUVECs were obtained from Lonza and cultured in MCDB131 medium (Gibco) supplemented with 2 mM L-glutamine (Gibco) and Low Serum Growth Supplement (Gibco), containing 2% v/v fetal bovine serum (FBS), 1 µg/ml hydrocortisone, 10 ng/ml human epidermal growth factor, 3 ng/ml basic fibroblast growth factor and 10 µg/ml heparin. HUVECs were passaged using trypsin/EDTA (0.05%; Gibco), and all experiments were performed using cells at passage 2–5. Primary HMVECs were purchased from American Type Culture Collection (ATCC) and cultured in Vascular Cell Basal Medium (ATCC) supplemented with the Microvascular Endothelial Cell Growth Kit-VEGF (ATCC). EA.hy926 cells were obtained from ATCC and cultured in Dulbecco's modified Eagle Medium (DMEM) (Gibco) supplemented with 10% v/v FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). Jurkat and THP-1 cells were obtained from ATCC and cultured in RPMI-1640 medium (Gibco) supplemented with 10% v/v FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Human neutrophils were isolated from freshly drawn anti-coagulated whole blood using a human MACSxpress™ Neutrophil Isolation Kit (Miltenyi Biotec), according to the manufacturer's recommendations. Isolated neutrophils were kept in serum-free RPMI-1640 medium and used in the experiments shortly after isolation. Cell culture was performed in a humidified incubator maintained at 37°C with 5% CO2 and 95% air. Cells were routinely tested for mycoplasma contamination.
Cells were lysed in ice-cold radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100 and 1% sodium deoxycholate) supplemented with protease inhibitors (Complete Protease Inhibitor Mixture Tablets, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail Tablets, Roche). Protein concentration was measured with a Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific), and equal amounts of proteins were separated by SDS–PAGE. Resolved proteins were transferred to a nitrocellulose membrane, which was then blocked with 5% skim milk. After blocking, membrane was probed with primary antibodies. Proteins were visualized with IRDye secondary antibodies and Odyssey Infrared Imaging System (LI-COR Biosciences UK) or horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako), LUMI-LIGHTPLUS WB Substrate (Roche) and the ImageQuant LAS 4000 imaging system (GE Healthcare). Intensities of immunoreactive bands were quantified by densitometry using Image Studio Ver. 4.0 software (LI-COR Biosciences UK).
NF-κB ELISA
Nuclear cell fractions were isolated using a Nuclear Extract Kit (Active Motif), and 2 μg nuclear extracts was used to quantify the activation of NF-κB transcription factors with the enzyme-linked immunosorbent assay (ELISA)-based TransAM NF-κB Family Transcription Factor Assay Kit (Active Motif), following the manufacturer's instructions. Nuclear extracts were plated in duplicates.
Quantitative RT-PCR
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) and reverse transcribed to complementary DNA (cDNA) using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems). Afterwards, 30 ng cDNA was used for quantitative PCR (qPCR) in a final volume of 10 µl, which contained TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and the specific TaqMan Gene Expression Assay for the gene studied (Applied Biosystems). The following Taqman Assays were used: CXCL1 (id: Hs00605382_gH), CXCL5 (id: Hs01099660_g1), CXCL8 (id: Hs00174103_m1), GM-CSF (id: Hs00929873_m1), CCL2 (id: Hs00234140_m1), CCL5 (id: Hs00982282_m1), CCL20 (id: Hs00355476_m1), ICAM-1 (id: Hs00164932_m1), VCAM-1 (id: Hs01003372_m1) and E-selectin (id: Hs00174057_m1). PCR amplification was performed with a QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems). The comparative ΔΔCT method was used for relative quantification of gene expression on triplicates of each reaction. EDF-1 was used as an endogenous control.
Multiplex cytokine assays
Cytokine levels were measured in cell culture medium using Meso Scale Discovery (MSD) ELISA according to the manufacturer's instructions. MSD plates were analyzed on the MS2400 imager (MSD). All standards and samples were measured in duplicates.
Membrane-based antibody array
Cytokine levels were measured in cell culture medium from control or LTβ-stimulated HMVECs with a Proteome Profiler Human XL Cytokine Array according to the protocol provided by the manufacturer. The arrays were scanned and quantified with ImageJ software (National Institutes of Health). Presented data show fold change in relative protein levels (normalized to array reference) in LTβ-stimulated HMVECs compared with control cells.
Adhesion assay
ECs were seeded in a black 96-well plate coated with 1% fibronectin at 1.2×105 cells per well in complete MCDB131 medium and grown for 2 days. Cells were then washed with PBS and stimulated for 24 h with LTβ in MCDB131 medium supplemented with 2% v/v FBS. In experiments with IKKβ and NIK inhibitors, HUVECs were treated with inhibitors for 30 min prior to stimulation with LTβ. On the day of the assay, Jurkat cells, THP-1 cells and neutrophils were washed with PBS and fluorescently stained with calcein-AM. After 30 min incubation at 37°C, calcein-labeled leukocytes were washed twice with serum-free RPMI-1640 medium and added to ECs in a 96-well plate. After 30–40 min incubation at 37°C, non-adherent calcein-labeled cells were extensively washed away with serum-free RPMI-1640 medium. Subsequently, fluorescence was measured with the Tecan SpectraFluor fluorescence plate reader using 485/530 nm excitation/emission filter sets. Each condition was tested in quadruplicates. Photos of calcein-labeled leukocytes attached to ECs were taken with a fluorescence microscope equipped with a 10× objective and a camera (Nikon Eclipse TE2000-S).
Endothelial permeability assay
Permeability across EC monolayers was measured using fibronectin-coated Transwell units (6.5 mm diameter, 0.4 μm pore size polycarbonate filter; Corning Costar). ECs were plated at density of 1.2×105 cells per Transwell unit (upper chamber) and cultured for 4 days until the formation of a tight monolayer. Cells were then washed with serum-free MCDB131 medium and stimulated for 24 h with LTβ or TNFα in complete MCDB131 medium. EC permeability was determined by measuring the passage of FITC-conjugated 10 kDa dextran (1mg/ml) through the EC monolayer. After 30 min of treatment, the amount of FITC-dextran diffused into the bottom chamber was evaluated by measuring the fluorescence in the medium collected from the lower compartment with the Tecan SpectraFluor fluorescence plate reader using 485/530 nm excitation/emission filter sets. Each condition was tested in quadruplicates.
ECs were transfected with siRNAs using Lipofectamine™ RNAiMAX Transfection Reagent (Thermo Fisher Scientific) as recommended by the manufacturer. The following siRNAs were used: NIK siRNA (Stealth siRNA, id: HSS113310, Invitrogen), NIK siRNA-2 (Silencer Select, id: s17188, Invitrogen), p100 siRNAs (Stealth siRNA, id: HSS107146 and HSS107147, Invitrogen), IKKα siRNAs (Stealth siRNA, id: HSS101936 and HSS101937, Invitrogen), IKKβ siRNA (siGENOME SMARTpool, M-003503-03-0005, Dharmacon), scrambled siRNAs [Stealth RNAi™ siRNA Negative Control Lo GC Duplex #3, Invitrogen (control for siNIK, sip100 and siIKKα); Silencer Select Negative Control No. 1 siRNA (control for siNIK-2); siControl Non-targeting siRNA pool, D-001206-13-20, Dharmacon (control for siIKKβ)]. After 5 h of transfection, ECs were washed twice with PBS and incubated with complete MCDB131 medium for 1–2 days prior to further analysis.
LDH viability assay
Toxicity of NIK inhibitor was assessed using an In Vitro Toxicology Assay Kit (Sigma-Aldrich), which measures the plasma membrane integrity as a function of the amount of cytoplasmic lactate dehydrogenase (LDH) released into the medium. Cells were incubated in medium containing 0.1, 1 or 10 µM NIK inhibitor or DMSO for 24 h or 48 h. Hereafter, medium was removed and the LDH activity was assayed according to the protocol provided by the manufacturer. All samples were measured in triplicates.
MTT viability assay
Toxicity of IKKβ inhibitor was assessed using MTT assay. Cells were incubated in medium containing 0.1, 1, 2.5, 5 or 10 µM IKKβ inhibitor or DMSO for 24 h or 48 h. Hereafter, medium was replaced by medium containing 1 mg/ml MTT (Sigma-Aldrich). After 2 h, medium was removed from wells and the reaction product, formazan, was solubilized using acidified isopropanol (4 mM HCl, 0.1% Igepal CA630, Sigma-Aldrich) and absorbance was measured at 595 nm. All samples were measured in triplicates.
Transduction with adenoviral vectors
Adenoviral vectors encoding GFP (AdGFP), wild-type NIK (AdNIK-WT) and kinase-dead NIK (AdNIK-KD) were kindly provided by Prof. D. Wallach, Weizmann Institute of Science, Israel (Ramakrishnan et al., 2004). Cells were transduced with vectors at various MOIs (indicated in the figure legends) in complete MCDB131 medium for 24 h, and then used for further analysis.
Statistical significance was evaluated with Student's two-tailed unpaired t-test (two groups) or one-way ANOVA and Tukey's HSD post hoc test (>2 groups). Significance of mean comparison is annotated as follows: ns, non-significant (P>0.05); *P≤0.05 and **P≤0.01.
P.K., E.I., M.F. and H.K.O. are employees of AstraZeneca, which supported the study. C.X.M., K.C.M.J., J.P.v.H. and S.W.T. declare no conflicts of interest.
Conceptualization: P.K., S.W.T., H.K.O.; Methodology: P.K., C.X.M., K.C.M.J., J.P.v.H., E.I.; Formal analysis: P.K., C.X.M., K.C.M.J., J.P.v.H., E.I.; Investigation: P.K., C.X.M., K.C.M.J.; Resources: M.F., S.W.T.; Data curation: P.K.; Writing - original draft: P.K., H.K.O.; Writing - review & editing: P.K., C.X.M., K.C.M.J., J.P.v.H., E.I., M.F., S.W.T., H.K.O.; Supervision: S.W.T., H.K.O.; Project administration: H.K.O.; Funding acquisition: H.K.O.
This study was supported by the internal AstraZeneca postdoc program [P.K.], and research grants from Reumafonds [13-3-304; 2016-1-032 to S.W.T., J.P.v.H. and K.C.M.J.] and Academisch Medisch Centrum/Universiteit van Amsterdam [C.X.M.].
Supplementary information available online at http://jcs.biologists.org/lookup/doi/10.1242/jcs.225615.supplemental
Received September 26, 2018.
© 2019. Published by The Company of Biologists Ltd
http://www.biologists.com/user-licence-1-1/
Adli, M.,
Merkhofer, E.,
Cogswell, P. and
Baldwin, A. S.
(2010). IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. PLoS ONE 5, e9428. doi:10.1371/journal.pone.0009428
Al-Soudi, A.,
Kaaij, M. H. and
Tas, S. W.
(2017). Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmun. Rev. 16, 951-962. doi:10.1016/j.autrev.2017.07.008
Andersson, P.,
Börjesson, L.,
Eriksson, C. and
Larsson, J.
(2008). A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingredient. Google Patents (WO 2008002246 A1).
Anest, V.,
Hanson, J. L.,
Cogswell, P. C.,
Steinbrecher, K. A.,
Strahl, B. D. and
(2003). A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423, 659-663. doi:10.1038/nature01648
Aya, K.,
Alhawagri, M.,
Hagen-Stapleton, A.,
Kitaura, H.,
Kanagawa, O. and
Veis Novack, D.
(2005). NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest. 115, 1848-1854. doi:10.1172/JCI23763
Bonizzi, G.,
Bebien, M.,
Otero, D. C.,
Johnson-Vroom, K. E.,
Cao, Y.,
Vu, D.,
Jegga, A. G.,
Aronow, B. J.,
Ghosh, G.,
Rickert, R. C. et al.
(2004). Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 23, 4202-4210. doi:10.1038/sj.emboj.7600391
Chang, Y. H.,
Hsieh, S. L.,
Chao, Y.,
Chou, Y. C. and
Lin, W. W.
(2005). Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells. J. Biomed. Sci. 12, 363-375. doi:10.1007/s11373-005-1360-5
Dejardin, E.,
Droin, N. M.,
Delhase, M.,
Haas, E.,
Makris, C.,
Li, Z.-W.,
Karin, M.,
Ware, C. F. and
Green, D. R.
(2002). The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17, 525-535. doi:10.1016/S1074-7613(02)00423-5
De Martin, R.,
Hoeth, M.,
Hofer-Warbinek, R. and
Schmid, J. A.
(2000). The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 20, E83-E88.
Elshabrawy, H. A.,
Volin, M. V.,
Ravella, S.,
Virupannavar, S. and
Shahrara, S.
(2015). The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18, 433-448. doi:10.1007/s10456-015-9477-2
Hayden, M. S. and
Ghosh, S.
(2004). Signaling to NF-kappaB. Genes Dev. 18, 2195-2224. doi:10.1101/gad.1228704
Hollenbaugh, D.,
Mischel-Petty, N.,
Edwards, C. P.,
Simon, J. C.,
Denfeld, R. W.,
Kiener, P. A. and
Aruffo, A.
(1995). Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182, 33-40. doi:10.1084/jem.182.1.33
Baud, V.,
Zhang, P.,
Deerinck, T.,
Ellisman, M.,
Johnson, R. and
Karin, M.
(1999). Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284, 316-320. doi:10.1126/science.284.5412.316
Huang, S.,
Robinson, J. B.,
Deguzman, A.,
Bucana, C. D. and
Fidler, I. J.
(2000). Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60, 5334-5339.
Humby, F.,
Bombardieri, M.,
Manzo, A.,
Kelly, S.,
Blades, M. C.,
Kirkham, B.,
Spencer, J. and
Pitzalis, C.
(2009). Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 6, e1. doi:10.1371/journal.pmed.0060001
Hynd, G.,
Price, S.,
Kulagowski, J.,
Macleod, C.,
Mann, S. E.,
Panchal, T. A.,
Tisselli, P. and
Montana, J. G.
(2014). 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine derivatives as Nik inhibitors for the treatment of cancer. Google Patents (WO 2014174021 A1).
Jones, G. W. and
Jones, S. A.
(2016). Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147, 141-151. doi:10.1111/imm.12554
Kempe, S.,
Kestler, H.,
Lasar, A. and
Wirth, T.
(2005). NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res. 33, 5308-5319. doi:10.1093/nar/gki836
Kew, R. R.,
Penzo, M.,
Habiel, D. M. and
Marcu, K. B.
(2012). The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J. Immunol. 188, 2380-2386. doi:10.4049/jimmunol.1102454
Kraan, M. C.,
Reece, R. J.,
Smeets, T. J. M.,
Veale, D. J.,
Emery, P. and
Tak, P. P.
(2002). Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis. Rheum. 46, 2034-2038. doi:10.1002/art.10556
Lau, T.-S.,
Chung, T. K.-H.,
Cheung, T.-H.,
Chan, L. K.-Y.,
Cheung, L. W.-H.,
Yim, S.-F.,
Siu, N. S.-S.,
Lo, K.-W.,
Yu, M. M.-Y.,
Kulbe, H. et al.
(2014). Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J. Pathol. 232, 43-56. doi:10.1002/path.4258
Lee, H.,
Herrmann, A.,
Deng, J. H.,
Kujawski, M.,
Niu, G.,
Forman, S.,
Jove, R.,
Pardoll, D. M. and
Yu, H.
(2009). Persistently activated Stat3 maintains constitutive NF-kappa B activity in tumors. Cancer Cell 15, 283-293. doi:10.1016/j.ccr.2009.02.015
Peet, G. W.,
Pullen, S. S.,
Schembri-King, J.,
Warren, T. C.,
Marcu, K. B.,
Kehry, M. R.,
Barton, R. and
Jakes, S.
(1998). Recombinant IkappaB kinases alpha and beta are direct kinases of Ikappa Balpha. J. Biol. Chem. 273, 30736-30741. doi:10.1074/jbc.273.46.30736
Li, Q.,
Lu, Q.,
Hwang, J. Y.,
Büscher, D.,
Lee, K.-F.,
Izpisua-Belmonte, J. C. and
Verma, I. M.
(1999). IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13, 1322-1328. doi:10.1101/gad.13.10.1322
Ling, L.,
Cao, Z. and
Goeddel, D. V.
(1998). NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA 95, 3792-3797. doi:10.1073/pnas.95.7.3792
Lovas, A.,
Radke, D.,
Albrecht, D.,
Yilmaz, Z. B.,
Möller, U.,
Habenicht, A. J. R. and
Weih, F.
(2008). Differential RelA- and RelB-dependent gene transcription in LTbetaR-stimulated mouse embryonic fibroblasts. BMC Genomics 9, 606. doi:10.1186/1471-2164-9-606
Madge, L. A.,
Kluger, M. S.,
Orange, J. S. and
May, M. J.
(2008). Lymphotoxin-alpha 1 beta 2 and LIGHT induce classical and noncanonical NF-kappa B-dependent proinflammatory gene expression in vascular endothelial cells. J. Immunol. 180, 3467-3477. doi:10.4049/jimmunol.180.5.3467
Maijer, K. I.,
Noort, A. R.,
de Hair, M. J. H.,
van der Leij, C.,
van Zoest, K. P. M.,
Choi, I. Y.,
Gerlag, D. M.,
Maas, M.,
Tak, P. P. and
(2015). Nuclear Factor-κB-inducing kinase is expressed in synovial endothelial cells in patients with early arthritis and correlates with markers of inflammation: a prospective cohort study. J. Rheumatol. 42, 1573-1581. doi:10.3899/jrheum.150245
Maracle, C. X.,
Kucharzewska, P.,
Helder, B.,
van der Horst, C.,
Correa de Sampaio, P.,
Noort, A.-R.,
van Zoest, K.,
Griffioen, A. W.,
Olsson, H. and
(2017). Targeting non-canonical nuclear factor-κB signalling attenuates neovascularization in a novel 3D model of rheumatoid arthritis synovial angiogenesis. Rheumatology 56, 294-302. doi:10.1093/rheumatology/kew393
Matsushima, A.,
Kaisho, T.,
Rennert, P. D.,
Nakano, H.,
Kurosawa, K.,
Uchida, D.,
Takeda, K.,
Akira, S. and
Matsumoto, M.
(2001). Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J. Exp. Med. 193, 631-636. doi:10.1084/jem.193.5.631
Müller, J. R. and
Siebenlist, U.
(2003). Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem. 278, 12006-12012. doi:10.1074/jbc.M210768200
Murdaca, G.,
Colombo, B. M.,
Cagnati, P.,
Gulli, R.,
Spanò, F. and
Puppo, F.
(2012). Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224, 309-317. doi:10.1016/j.atherosclerosis.2012.05.013
Nadiminty, N.,
Chun, J. Y.,
Dutt, S.,
Lin, X. and
Gao, A. C.
(2007). LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem. Biophys. Res. Commun. 359, 379-384. doi:10.1016/j.bbrc.2007.05.119
Napetschnig, J. and
Wu, H.
(2013). Molecular basis of NF-κB signaling. Annu. Rev. Biophys. 42, 443-468. doi:10.1146/annurev-biophys-083012-130338
Weijers, E. M.,
Koolwijk, P.,
Novack, D. V.,
Siemerink, M. J.,
Schlingemann, R. O.,
(2014). NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis. J. Pathol. 234, 375-385. doi:10.1002/path.4403
van Zoest, K. P.,
van Baarsen, L. G.,
Papazian, N.,
Romera-Hernandez, M.,
Tak, P. P.,
Cupedo, T. and
(2015a). Tertiary lymphoid structures in rheumatoid arthritis: NF-κB-Inducing kinase-positive endothelial cells as central players. Am. J. Pathol. 185, 1935-1943. doi:10.1016/j.ajpath.2015.03.012
(2015b). Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res. Ther. 17, 15. doi:10.1186/s13075-015-0527-3
Yin, L.,
Schreiber, R. D.,
Goeddel, D. V.,
Ross, F. P. and
Teitelbaum, S. L.
(2003). The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198, 771-781. doi:10.1084/jem.20030116
O'Mahony, A.,
Geleziunas, R. and
Greene, W. C.
(2000). Activation of the heterodimeric IKKalpha-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol. Cell. Biol. 20, 1170-1178. doi:10.1128/MCB.20.4.1170-1178.2000
Onder, L.,
Danuser, R.,
Scandella, E.,
Firner, S.,
Chai, Q.,
Hehlgans, T.,
Stein, J. V. and
Ludewig, B.
(2013). Endothelial cellspecific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med. 210, 465-473. doi:10.1084/jem.20121462
Park, G. Y.,
Wang, X.,
Hu, N.,
Pedchenko, T. V.,
Blackwell, T. S. and
Christman, J. W.
(2006). NIK is involved in nucleosomal regulation by enhancing histone H3 phosphorylation by IKKalpha. J. Biol. Chem. 281, 18684-18690. doi:10.1074/jbc.M600733200
Pitzalis, C.,
Jones, G. W.,
Bombardieri, M. and
(2014). Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447-462. doi:10.1038/nri3700
Pober, J. S. and
Sessa, W. C.
(2007). Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 10, 803-815. doi:10.1038/nri2171
Ramakrishnan, P.,
Wang, W. and
Wallach, D.
(2004). Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 21, 477-489. doi:10.1016/j.immuni.2004.08.009
Scheinman, R. I.,
Beg, A. A. and
Baldwin, A. S. Jr.
(1993). NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol. Cell. Biol. 13, 6089-6101. doi:10.1128/MCB.13.10.6089
Seigner, J.,
Basilio, J.,
Resch, U. and
de Martin, R.
(2018). CD40L and TNF both activate the classical NF-κB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells. Biochem. Biophys. Res. Commun. 495, 1389-1394. doi:10.1016/j.bbrc.2017.11.160
Smith, C.,
Andreakos, E.,
Crawley, J. B.,
Brennan, F. M.,
Feldmann, M. and
Foxwell, B. M. J.
(2001). NF-κB-Inducing Kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts. J. Immunol. 167, 5895-5903. doi:10.4049/jimmunol.167.10.5895
Steyers, C. M. and
Miller, F. J. Jr.
(2014). Endothelial dysfunction in chronic inflammatory diseases. Int. J. Mol. Sci. 15, 11324-11349. doi:10.3390/ijms150711324
Sun, S.-C.
(2017). The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545-558. doi:10.1038/nri.2017.52
Tanaka, M.,
Fuentes, M. E.,
Durnin, M. H.,
Dalrymple, S. A.,
Hardy, K. L. and
(1999). Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKKb-deficient mice. Immunity 10, 421-429. doi:10.1016/S1074-7613(00)80042-4
Tas, S. W.,
Balogh, E. and
Szekanecz, Z.
(2016). Targeting of proangiogenic signalling pathways in chronic inflammation. Nat. Rev. Rheumatol. 12, 111-122. doi:10.1038/nrrheum.2015.164
Wolf, M. J.,
Seleznik, G. M.,
Zeller, N. and
Heikenwalder, M.
(2010). The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. Oncogene 29, 5006-5018. doi:10.1038/onc.2010.260
Woronicz, J. D.,
Cao, Z.,
Rothe, M. and
(1997). IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278, 866-869. doi:10.1126/science.278.5339.866
Xiao, G.,
Harhaj, E. W. and
(2001). NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell. 7, 401-409. doi:10.1016/S1097-2765(01)00187-3
Yamamoto, Y.,
Yin, M.-J. and
Gaynor, R. B.
(2000). IKKα regulation of IKKβ kinase activity. Mol. Cell. Biol. 20, 3655-3666. doi:10.1128/MCB.20.10.3655-3666.2000
Verma, U. N.,
Prajapati, S.,
Kwak, Y.-T. and
(2003). Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423, 655-659. doi:10.1038/nature01576
Wu, L.,
Wesche, H.,
Arthur, C. D.,
White, J. M.,
Goeddel, D. V. and
Schreiber, R. D.
(2001). Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 291, 2162-2165. doi:10.1126/science.1058453
Yoon, S.,
Woo, S. U.,
Kang, J. H.,
Kim, K.,
Shin, H.-J.,
Gwak, H.-S.,
Park, S. and
Chwae, Y.-J.
(2012). NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells. Oncogene 31, 3467-3481. doi:10.1038/onc.2011.517
Yu, J.,
Yan, F.,
Zhao, H.,
Yan, C.,
Yan, F. and
(2014). Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 193, 2574-2586. doi:10.4049/jimmunol.1400833
Zarnegar, B.,
Yamazaki, S.,
He, J. Q. and
Cheng, G.
(2008). Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc. Natl. Acad. Sci. USA 105, 3503-3508. doi:10.1073/pnas.0707959105
NF-κB-inducing kinase
Lymphotoxin-β receptor
LTβR
Endothelial cells
Thank you for your interest in spreading the word on Journal of Cell Science.
You are going to email the following NIK–IKK complex interaction controls NF-κB-dependent inflammatory activation of endothelium in response to LTβR ligation
Message Subject (Your Name) has sent you a message from Journal of Cell Science
Message Body (Your Name) thought you would like to see the Journal of Cell Science web site.
Histone chaperone APLF level dictates the implantation of mouse embryos
Switching between blebbing and lamellipodia depends on the degree of non-muscle myosin II activity
Kindlin-2 promotes rear focal adhesion disassembly and directional persistence during cell migration
Show more RESEARCH ARTICLE
Other journals from The Company of Biologists
2020 at The Company of Biologists
Despite the challenges of 2020, we were able to bring a number of long-term projects and new ventures to fruition. While we look forward to a new year, join us as we reflect on the triumphs of the last 12 months.
Mole – The Corona Files
"This is not going to go away, 'like a miracle.' We have to do magic. And I know we can."
Mole continues to offer his wise words to researchers on how to manage during the COVID-19 pandemic.
Cell scientist to watch – Christine Faulkner
In an interview, Christine Faulkner talks about where her interest in plant science began, how she found the transition between Australia and the UK, and shares her thoughts on virtual conferences.
Read & Publish participation extends worldwide
"The clear advantages are rapid and efficient exposure and easy access to my article around the world. I believe it is great to have this publishing option in fast-growing fields in biomedical research."
Dr Jaceques Behmoaras (Imperial College London) shares his experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 60 institutions in 12 countries taking part – find out more and view our full list of participating institutions.
JCS and COVID-19
For more information on measures Journal of Cell Science is taking to support the community during the COVID-19 pandemic, please see here.
If you have any questions or concerns, please do not hestiate to contact the Editorial Office.


text:
Construction firm MMP Resources acquiring S$25m stake in natural gas JV company
Wed, Dec 05, 2018 - 9:07 AM
Lynette Tantanlyn@sph.com.sg@LynetteTanBT
CONSTRUCTION company MMP Resources is acquiring a 50 per cent stake in a joint venture company that owns an operating gas field in Russia for S$25 million. It will also be deemed a "mineral, oil and gas company" post-acquisition.
According to an exchange filing on Wednesday, MMP entered into a binding term sheet to purchase the stake in the joint venture company from Lloyds Energy Ltd, a "gas to wire" liquefied natural gas (LNG) player which produces, stores and sells LNG.
The joint venture company owns the Asia One gas field in Russia's North-West region, valued at S$50 million by MMP-appointed independent valuer Gaffney, Cline & Associates.
MMP will pay Lloyds cash - in a first tranche of S$250,000 and the remaining sum in a second tranche. But, Lloyds can opt to be paid the second tranche fully or partially with shares in MMP.
On Oct 25, MMP announced that a number of its substantial shareholders entered into a non-binding term sheet to potentially sell their shares to Lloyds, which could result in Lloyds acquiring more than 30 per cent of the company's shares, triggering a mandatory general offer.
SEE ALSO: MMP Resources terminates term sheet for Russian acquisition
Mainboard-listed MMP said it is looking to diversify into the natural gas and energy business to provide shareholders with better returns and long-term growth. Following the acquisition, the company will be a "mineral, oil and gas company". In addition, the company intends to dispose its existing Japanese assets after the acquisition.
MMP did not name the joint venture company, incorporated in Russia, but said it mainly supplies natural gas.
MMP Resources
Lloyds Energy
Tokyo's Nikkei closes down nearly 2%
Singapore stocks: STI resumes Thursday afternoon at 3,355.05, down 0.29% on day

redpajama_set_name: RedPajamaCommonCrawl


Knicks point guard Raymond Felton (with ball) drives to the basket as Heat's center Joel Anthony (right) defends.
MIAMI – Raymond Felton scored a season-high 27 points, and the Knicks connected on 18 3-pointers to more than offset the absence of Carmelo Anthony while dominating Miami Heat for the second time this season, beating them 112-92 last night.
Steve Novak scored 18 points, J.R. Smith added 13 and Tyson Chandler scored 13 for the Knicks, who won their fifth straight and moved 1 1/2 games clear of Miami for the best record in the Eastern Conference.
The Knicks made eight 3-pointers in the third quarter alone, the most by any NBA team in any quarter so far this season.
Anthony sat out, one night after needing five stitches to close a cut on the middle finger of his left hand.LeBron James nearly picked up his second straight triple-double – 31 points, 10 rebounds, nine assists – in Miami's second straight loss, the first of those coming on the road against lowly Washington on Tuesday.
Dwyane Wade scored 13 points, Chris Bosh had 12 and Udonis Haslem added 10 for the Heat, who fell to 8-1 at home.
Rasheed Wallace scored 12 points and Jason Kidd added 11 for the Knicks, who finished 18 of 44 from 3-point range.


Benfleet is a small town in Essex, a few miles to the West of Southend. It is sometimes known as South Benfleet, to distinguish it from North Benfleet a few miles away.
Formerly a fishing village, it stands on Benfleet Creek, an arm of the estuary of the River Thames.
A bridge links Benfleet to Canvey Island.
In 894, the Battle of Benfleet was an English victory against the Danish forces of Hasten, who had left a small garrison behind while he harried other parts of the country.
Blue Badge Guide Colin Crosby is available to lead Guided Walks around Benfleet for groups.


The Holiday dessert extravaganza continues! Between my Paleo Classic Pumpkin Pie, the Ginger Pear Upside Down Cake I posted earlier this week, and this uh.maz.ing Salted Maple Pecan Pie, I'd say your Holiday dessert plan is off to a great start! At our holiday functions, pecan pie and pumpkin pie are the two must haves. My mom's favorite pie has always been pecan, and you've gotta do things just for mom when you can. And my favorite is pumpkin pie, so obviously I'm making that. And dad's favorite is whatever pie is available, so he's happy too.


text:
Postcards From San Antonio -- Sunday
SAN ANTONIO, Texas–The "off day" between the national semi-finals and the title game is anything but that. Both Georgia Tech and UConn had NCAA required media obligations for the better part of 90 minutes this afternoon. Tech head coach Paul Hewitt answered an array of questions about the ball game against the Huskies and his coaching experiences from high school through his current post in Atlanta.
See the complete Press Conference Transcript.
Tech will meet UConn for the second time this season on Monday night. The Yellow Jackets beat the Huskies, 77-61, on November 26, at Madison Square Garden. There are several personnel differences between that game and this one for each school. Georgia Tech was without Theodis Tarver (knee injury) and Will Bynum (transfer eligibility), while Connecticut was missing 6'11 forward Charlie Villanueva (NCAA eligibility issues). The Huskies no longer have guard Marcus Washington (academics) and forward Marcus White to use from their depth.
THE JACKETS VISIT MR. ROBINSON
One of the highlights of Georgia Tech's trip to San Antonio was Friday afternoon's visit to Carver Academy, the independent private school founded by NBA great David Robinson to provide educational opportunities for children from ethnically and culturally diverse backgrounds.
Robinson, who retired from the San Antonio Spurs following last season's NBA title, was a U.S. Naval Academy classmate of Tech senior associate director of athletics Mary McElroy. Robinson spoke to the Tech team Friday and is expected to attend Monday's championship game.
Tech head coach Paul Hewitt has requested that Tech fans and supporters who would like to wish the team well should send small donations to Carver Academy in lieu of flowers, cookies, balloons, etc. Donations can be sent to The Carver Academy, on behalf of Georgia Tech Basketball, 217 Robinson Place, San Antonio, TX 78202. Fans can also visit the school's official website.
ALUMNI REPORT
The history of Georgia Tech basketball has been documented several different ways in the days leading up to Saturday's game against Oklahoma State. But the sight at the Alamodome against the Cowboys was second to none. On the radio, I said the "famous and infamous" were gathered, but one row of seats in the Tech section featured Dennis Scott, John Salley, Mark Price, Matt Harpring, John Kelly, Brian Domalik, Jon Babul, Winston Neal and former assistant coaches Kevin Cantwell and George Felton. A row below was former head coach Bobby Cremins, along with additional players and assistants. Tech great Roger Kaiser is here along with others from an era that precedes Coach Cremins. Off the top of my head, I would say that roughly three dozen basketball letterman are in attendance this weekend.
Expected in on Monday night are Chris Bosh, Kenny Anderson and possibly Stephon Marbury.
TECH TIES WINS MARK
The win over Oklahoma State also gave Tech its 28th win of the season, equaling the mark for most victories in a season by a Tech team that was set in 1990. Tomorrow night against the Huskies, Tech will try and set a new standard for wins in a campaign.


Welcome to Havering - a great place to live and work!
Havering is an Outer London Borough located in East London. The principal town in Havering is Romford and the other main communities are Hornchurch, Upminster and Rainham. The borough is mainly characterised by suburban development with some beautiful large areas of protected open space providing the best of both greenery and being located just a 20 minute train ride to the city of London.
As the third largest London Borough we are part of a rich mix of foundation, community, voluntary aided schools plus academies to give the perfect opportunity for career development.
We look forward to welcoming you to Havering to join us in ensuring that all children and young people have the best start in life.


With fall just around the corner, the time for school has started again. For many parents, this is a welcome relief to long days of "boredom" and daycare, and a shift back to learning. But for some families, back to school time is nothing but a battle. From bedtime to breakfast, check out these tips to make sure your child has a great school year!
Most of the back to school woes can be headed off with effective planning. Does your teen struggle to get out the door in the morning? Time management skills can help! Help her start the day off right by packing bags and choosing a great new outfit the night before. Once she's prepped, all she has to do is roll out of bed, spend time on hygiene, and grab those pre-packed bags. This can also be a great tip for busy parents who are rushing around to get lunches in order, coordinate the carpool, and everything else.
Especially if your child has struggled at school in the past, set clear expectations to prepare for success. Focus on actions, not results: instead of demanding A and B grades in math, demand that math gets studied for 30 minutes or so per day. This will help your child to see how their hard work turns into real accomplishments. Involve your child in setting goals so he learns the importance of monitoring and being aware of his own behaviors. Some great ideas to set expectations for the school year include homework time, study time, bed time, socialization, and behavior. If you need help with difficult or escalated issues, consider visiting a Littleton child behavior psychologist for custom help.
Didn't the kids just get the summer off? Still, down time is important, especially when one has been used to unlimited amounts! Many schools have taken advantage of a partial week to start off the school year, and for good reason—down time helps to recharge and revitalize. Make sure that you promote balance for your children by letting them know that down time and fun time are still important.
For many children, these tips are enough to ensure success. Others may need more personalized attention. If the normal tips aren't working for your child, or if you need special ideas for your child with learning differences or ADHD, consult a child psychologist in Littleton for more help. Dr. Lazarus has helped many families see success in all they do!